Medscape is available in 5 Language Editions – Choose your Edition here.


Lichen Amyloidosis Medication

  • Author: Sultan Al-Khenaizan, MBBS, FRCPC; Chief Editor: William D James, MD  more...
Updated: Dec 11, 2015

Medication Summary

The goal of pharmacotherapy for lichen amyloidosis is to reduce morbidity.



Class Summary

These agents act by competitive inhibition of histamine at the H1 receptor. They may control itching by blocking effects of endogenously released histamine.

Chlorpheniramine (Chlor-Trimeton)


Competes with histamine or H1 receptor sites on effector cells in blood vessels and respiratory tract.

Diphenhydramine (Benadryl)


For symptomatic relief of symptoms caused by release of histamine in allergic reactions.


Topical anti-inflammatory agents

Class Summary

This agent is an industrial solvent.

Dimethyl sulfoxide (Rimso-50)


May help relieve symptoms. DMSO, an oxidation product of dimethyl sulfide, is an exceptional solvent possessing a number of commercial uses.

Not an FDA-approved indication.

Contributor Information and Disclosures

Sultan Al-Khenaizan, MBBS, FRCPC Consulting Staff, Departments of Dermatology and Internal Medicine, King Fahad National Guard Hospital, Saudi Arabia

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Warren R Heymann, MD Head, Division of Dermatology, Professor, Department of Internal Medicine, Rutgers New Jersey Medical School

Warren R Heymann, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Chief Editor

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Catharine Lisa Kauffman, MD, FACP Georgetown Dermatology and Georgetown Dermpath

Catharine Lisa Kauffman, MD, FACP is a member of the following medical societies: American Academy of Dermatology, Royal Society of Medicine, Women's Dermatologic Society, American Medical Association, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

  1. Eanes ED, Glenner GG. X-ray diffraction studies on amyloid filaments. J Histochem Cytochem. 1968 Nov. 16(11):673-7. [Medline].

  2. Bugalho MJ, Limbert E, Sobrinho LG, et al. A kindred with multiple endocrine neoplasia type 2A associated with pruritic skin lesions. Cancer. 1992 Dec 1. 70(11):2664-7. [Medline].

  3. Chabre O, Labat F, Pinel N, Berthod F, Tarel V, Bachelot I. Cutaneous lesion associated with multiple endocrine neoplasia type 2A: lichen amyloidosis or notalgia paresthetica?. Henry Ford Hosp Med J. 1992. 40(3-4):245-8. [Medline].

  4. Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med. 1989 Nov 15. 111(10):802-6. [Medline].

  5. Kousseff BG, Espinoza C, Zamore GA. Sipple syndrome with lichen amyloidosis as a paracrinopathy: pleiotropy, heterogeneity, or a contiguous gene?. J Am Acad Dermatol. 1991 Oct. 25(4):651-7. [Medline].

  6. Kousseff BG. Multiple endocrine neoplasia 2 (MEN 2)/MEN 2A (Sipple syndrome). Dermatol Clin. 1995 Jan. 13(1):91-7. [Medline].

  7. Nunziata V, di Giovanni G, Lettera AM, D'Armiento M, Mancini M. Cutaneous lichen amyloidosis associated with multiple endocrine neoplasia type 2A. Henry Ford Hosp Med J. 1989. 37(3-4):144-6. [Medline].

  8. Pacini F, Fugazzola L, Bevilacqua G, Viacava P, Nardini V, Martino E. Multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis: description of a new family. J Endocrinol Invest. 1993 Apr. 16(4):295-6. [Medline].

  9. Robinson MF, Furst EJ, Nunziata V, et al. Characterization of the clinical features of five families with hereditary primary cutaneous lichen amyloidosis and multiple endocrine neoplasia type 2. Henry Ford Hosp Med J. 1992. 40(3-4):249-52. [Medline].

  10. Rothberg AE, Raymond VM, Gruber SB, Sisson J. Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Thyroid. 2009 Jun. 19(6):651-5. [Medline].

  11. Doutre MS, Beylot C, Couzigou P, Beraud C. Lichen amyloidosis in Alagille syndrome. Arch Dermatol. 1991 Oct. 127(10):1590-1. [Medline].

  12. Maddison B, Namazi MR, Samuel LS, et al. Unexpected diminished innervation of epidermis and dermoepidermal junction in lichen amyloidosus. Br J Dermatol. 2008 Aug. 159(2):403-6. [Medline].

  13. Apaydin R, Gurbuz Y, Bayramgurler D, Muezzinoglu B, Bilen N. Cytokeratin expression in lichen amyloidosus and macular amyloidosis. J Eur Acad Dermatol Venereol. 2004 May. 18(3):305-9. [Medline].

  14. Weyers W, Weyers I, Bonczkowitz M, Diaz-Cascajo C, Schill WB. Lichen amyloidosus: a consequence of scratching. J Am Acad Dermatol. 1997 Dec. 37(6):923-8. [Medline].

  15. Tanaka A, Arita K, Lai-Cheong JE, Palisson F, Hide M, McGrath JA. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol. 2009 Dec. 161(6):1217-24. [Medline].

  16. Frolich M, Enk A, Diepgen TL, Weisshaar E. Successful treatment of therapy-resistant pruritus in lichen amyloidosis with menthol. Acta Derm Venereol. 2009. 89(5):524-6. [Medline].

  17. Castanedo-Cazares JP, Lepe V, Moncada B. Lichen amyloidosis improved by 0.1% topical tacrolimus. Dermatology. 2002. 205(4):420-1. [Medline].

  18. Hsieh SD, Yamamoto R, Saito K, et al. Amyloidosis presented with whitening and loss of hair which improved after dimethylsulfoxide (DMSO) treatment. Jpn J Med. 1987 Aug. 26(3):393-5. [Medline].

  19. Lim KB, Tan SH, Tan KT. Lack of effect of dimethyl sulphoxide (DMSO) on amyloid deposits in lichen amyloidosis. Br J Dermatol. 1988 Sep. 119(3):409-10. [Medline].

  20. Ozkaya-Bayazit E, Kavak A, Gungor H, Ozarmagan G. Intermittent use of topical dimethyl sulfoxide in macular and papular amyloidosis. Int J Dermatol. 1998 Dec. 37(12):949-54. [Medline].

  21. Pandhi R, Kaur I, Kumar B. Lack of effect of dimethylsulphoxide in cutaneous amyloidosis. J Dermatolog Treat. 2002 Mar. 13(1):11-4. [Medline].

  22. Aram H. Failure of etretinate (RO 10-9359) in lichen amyloidosus. Int J Dermatol. 1986 Apr. 25(3):206. [Medline].

  23. David M, Ingber A, Ben-Chetrit A, Sandbank J, Sandbank M. Effect of etretinate on lichen amyloidosus. Dermatologica. 1987. 175(6):302-3. [Medline].

  24. Marschalko M, Daroczy J, Soos G. Etretinate for the treatment of lichen amyloidosis. Arch Dermatol. 1988 May. 124(5):657-9. [Medline].

  25. Choi JY, Sippe J, Lee S. Acitretin for lichen amyloidosus. Australas J Dermatol. 2008 May. 49(2):109-13. [Medline].

  26. Carlesimo M, Narcisi A, Orsini D, Mari E, Di Russo P, Arcese A, et al. A case of lichen amyloidosus treated with acitretin. Clin Ter. 2011 Mar-Apr. 162(2):e59-61. [Medline].

  27. Sawamura D, Sato-Matsumura KC, Shibaki A, Akiyama M, Kikuchi T, Shimizu H. A case of lichen amyloidosis treated with pulsed dye laser. J Eur Acad Dermatol Venereol. 2005 Mar. 19(2):262-3. [Medline].

  28. Parsi K, Kossard S. Thermosensitive lichen amyloidosis. Int J Dermatol. 2004 Dec. 43(12):925-8. [Medline].

  29. Aoki M, Kawana S. Lichen amyloidosis of the auricular concha: successful treatment with electrodesiccation. J Dermatol. 2009 Feb. 36(2):116-7. [Medline].

  30. Terao M, Nishida K, Murota H, Katayama I. Clinical effect of tocoretinate on lichen and macular amyloidosis. J Dermatol. 2011 Feb. 38(2):179-84. [Medline].

  31. Esmat SM, Fawzi MM, Gawdat HI, Ali HS, Sayed SS. Efficacy of different modes of fractional CO2 laser in the treatment of primary cutaneous amyloidosis: A randomized clinical trial. Lasers Surg Med. 2015 Jul. 47 (5):388-95. [Medline].

  32. Norisugi O, Yamakoshi T, Shimizu T. Successful treatment of lichen amyloidosis using a CO2 surgical laser. Dermatol Ther. 2014 Mar-Apr. 27 (2):71-3. [Medline].

  33. Ostovari N, Mohtasham N, Oadras MS, Malekzad F. 532-nm and 1064-nm Q-switched Nd:YAG laser therapy for reduction of pigmentation in macular amyloidosis patches. J Eur Acad Dermatol Venereol. 2008 Apr. 22(4):442-6. [Medline].

  34. Breathnach SM, Bhogal B, Dyck RF, De Beer FC, Black MM, Pepys MB. Immunohistochemical demonstration of amyloid P component in skin of normal subjects and patients with cutaneous amyloidosis. Br J Dermatol. 1981 Aug. 105(2):115-24. [Medline].

  35. Breathnach SM, Melrose SM, Bhogal B, et al. Amyloid P component is located on elastic fibre microfibrils in normal human tissue. Nature. 1981 Oct 22. 293(5834):652-4. [Medline].

  36. Eriksson S, Janciauskiene S, Merlini G. The putative role of alpha-1-antitrypsin in the disaggregation of amyloid lambda fibrils. J Intern Med. 1995 Feb. 237(2):143-9. [Medline].

  37. Kuligowski ME, Chang A. Non-itchy lichen amyloidosus. Int J Dermatol. 1992 Oct. 31(10):747. [Medline].

  38. Lambert WC. Cutaneous deposition disorders. Farmer ER, Hood AF, eds. Pathology of the Skin. Norwalk, Conn: Appleton & Lange; 1990. Vol 432: 50.

  39. Li JJ, McAdam KP. Human amyloid P component: an elastase inhibitor. Scand J Immunol. 1984 Sep. 20(3):219-26. [Medline].

  40. Monfrecola G, Iandoli R, Bruno G, Martellotta D. Lichen amyloidosus: a new therapeutic approach. Acta Derm Venereol. 1985. 65(5):453-5. [Medline].

  41. Piette WW. Myeloma, paraproteinemias, and the skin. Med Clin North Am. 1986 Jan. 70(1):155-76. [Medline].

  42. Ruzicka T, Donhauser G, Linke RP, Landthaler M, Bieber T. [Cutaneous amyloidoses]. Hautarzt. 1990 May. 41(5):245-55. [Medline].

  43. Shirahama T, Cohen AS. High-resolution electron microscopic analysis of the amyloid fibril. J Cell Biol. 1967 Jun. 33(3):679-708. [Medline].

  44. Touart DM, Sau P. Cutaneous deposition diseases. Part I. J Am Acad Dermatol. 1998 Aug. 39(2 Pt 1):149-71; quiz 172-4. [Medline].

  45. Wang WJ. Clinical features of cutaneous amyloidoses. Clin Dermatol. 1990 Apr-Jun. 8(2):13-9. [Medline].

  46. Wong CK. Lichen amyloidosus. A relatively common skin disorder in Taiwan. Arch Dermatol. 1974 Sep. 110(3):438-40. [Medline].

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.